losartan potassium

Also found in: Dictionary, Acronyms.
Related to losartan potassium: lisinopril

losartan potassium


Pharmacologic class: Angiotensin II receptor antagonist

Therapeutic class: Antihypertensive

Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA Box Warning

• When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.


Blocks vasoconstricting and aldosterone-secreting effects of angiotensin II at various receptor sites, including vascular smooth muscle and adrenal glands. Also increases urinary flow and enhances excretion of chloride, magnesium, calcium, and phosphate.


Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages


Adults: Initially, 50 mg/day P.O.; range is 25 to 100 mg/day as a single dose or in two divided doses. May be used alone or with other drugs.

Children ages 6 and older: 0.7 mg/kg P.O. daily, up to total of 50 mg

To prevent cerebrovascular accident (stroke) in hypertensive patients with left ventricular hypertrophy (LVH)

Adults: Initially, 50 mg P.O. daily, increased to 100 mg P.O. daily. May be given concurrently with hydrochlorothiazide.

Nephropathy in patients with type 2 diabetes

Adults: 50 mg/day P.O.; increase to 100 mg/day based on blood pressure response.

Dosage adjustment

• Hepatic impairment

• Concurrent diuretic therapy


• Hypersensitivity to drug or its components

• Pregnancy (second and third trimesters)


Use cautiously in:

• heart failure, renal or hepatic impairment, obstructive biliary disorders

• high-dose diuretic therapy

• black patients

• pregnant patients (first trimester) or breastfeeding patients

• children younger than age 6 (safety not established).


• Administer with or without food.

• Know that if drug efficacy (measured at trough) is inadequate with once-daily dosing, prescriber may switch to twice-daily regimen using same or higher daily dosage.

• Be aware that drug may take 3 to 6 weeks to reach maximal efficacy.

Adverse reactions

CNS: dizziness, insomnia, headache, asthenia, fatigue

CV: hypotension

EENT: sinus disorders

GI: nausea, vomiting, diarrhea, dyspepsia, abdominal pain

Metabolic: hyperkalemia

Musculoskeletal: joint pain, back pain, muscle cramps

Respiratory: symptoms of upper respiratory infection, dry cough

Other: hypersensitivity reactions including angioedema


Drug-drug. Diuretics, other antihypertensives: increased risk of hypotension

Fluconazole: inhibited losartan metabolism, increased antihypertensive effects

Indomethacin: decreased losartan effects

Lithium: decreased lithium metabolism

Nonsteroidal anti-inflammatory drugs: decreased renal function

Potassium-sparing diuretics, potassium supplements: hyperkalemia

Rifamycins: enhanced losartan metabolism, decreased antihypertensive effects

Drug-diagnostic tests. Albumin: increased level

Drug-food. Salt substitutes containing potassium: hyperkalemia

Patient monitoring

Watch for angioedema and other hypersensitivity reactions.

• Monitor blood pressure to evaluate drug efficacy.

• Assess liver and kidney function tests and electrolyte levels.

• Stay alert for oliguria, progressive azotemia, and renal failure in patients with severe heart failure whose renal function depends on the renin-angiotensin-aldosterone system.

• Know that in black patients, losartan and other ACE inhibitors may be ineffective when used alone. Drug isn't indicated for stroke prevention in black hypertensive patients with LVH.

• Be aware that drug may cause fetal injury or death when used during second or third trimester of pregnancy.

Patient teaching

• Instruct patient to avoid potassium supplements and salt substitutes containing potassium, unless directed by prescriber.

Caution female patient not to take drug during second or third trimester of pregnancy. Advise her to contact prescriber immediately if she suspects pregnancy.

• Tell female patient to discuss breastfeeding with prescriber before taking.

Instruct patient to immediately report hypersensitivity reactions, especially lip or eyelid swelling, throat tightness, and difficulty breathing.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, nephropathy in Type 2 diabetic patients and is packaged in 90-count and 1000-count bottles.
Patients that have been prescribed the recalled losartan potassium tablets should continue to take the medication as the risk of stopping treatment without an alternative treatment plan is higher than continuing to take the affected medication.
The company received final FDA approval and launched the 100 mg/12.5 mg strength of Losartan Potassium and HCTZ Tablets in April 2010.
The recall affects Losartan Potassium tablets USP in 25, 50 and 100 mg doses.
unit has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength), the company said.
The NMBA impurity affects 36 lots of Losartan potassium tablets USP and 68 lots of Losartan potassium/hydrochlorothiazide tablets, USP.
Losartan Potassium and HCTZ Tablets, 50 mg/12.5 mg and 100 mg/25 mg, had US sales of approximately USD570m (EUR404.5m) and Losartan Potassium Tablets had US sales of approximately USD940m for the 12 months ending 30 June 2010, according to IMS Health.
Losartan potassium tablets USP, Teva Pharmaceuticals USA
The approval is for Losartan Potassium tablets and Losartan Potassium plus Hydrochlorothiazide.
Following a rash of blood pressure medication (https://www.ibtimes.com/blood-pressure-medication-recall-2019-cancer-causing-impurity-prompts-recall-2768156) recalls over the last two months, (https://www.fda.gov/Safety/Recalls/ucm632395.htm) Camber Pharmaceuticals has also recalled 87 lots of Losartan Potassium tablets USP for the detection of a cancer-causing impurity.
Merck & Co.'s Hyzaar is known as losartan potassium and hydrochiorothiazide (HCTZ) tablets, and Merck's Cozaar is known as losartan potassium tablets.